All national guidelines for the management of hypertension recommend angiotensin
receptor blockers (ARBs) as an initial or add-on antihypertensive therapy. The eight …

Metabolic syndrome (MetS), a cluster of dyslipidaemia, central obesity, hypertension and/or
insulin resistance, is associated with increased cardiovascular disease (CVD) type 2 …

Valsartan (VST) is a poorly soluble antihypertensive drug characterized by its limited
dissolution rate and low bioavailability. This study aims to improve VST solubility and …

INTRODUCTION Chronic kidney disease (CKD) is a progressive and irreversible
impairment of kidney function; if it progresses to the end-stage of CKD, dialysis or kidney …

Background Diabetic nephropathy (DN) is one of the most serious microvascular
complications of diabetes, valsartan and α-lipoic acid alone or in combination has been …

In Germany,~ 8 million patients take angiotensin receptor blockers (ARBs) and 2.25 million
of them valsartan. In 2018, contamination of generic ARBs with probable carcinogenic …

We evaluated whether aliskiren, valsartan, or a combination of both was protective following
myocardial infarction (MI) through effects on matrix metalloproteinase (MMP)-9. C57BL/6J …

We describe a simple, metal-free regioselective N2-arylation strategy for 5-substituted-1 H-
tetrazoles with diaryliodonium salts to access 2-aryl-5-substituted-tetrazoles. Diaryliodonium …

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. A
total of 28 new molecular entities (NMEs) were approved by the US Food and Drug …

Hypertension has a major associated risk for organ damage and mortality, which is further
heightened in patients with prior cardiovascular (CV) events, comorbid diabetes mellitus …